Professor Anthony Schapira was appointed in 1990 as chairman of the University Department of Clinical Neurosciences at the UCL Queen Square Institute of Neurology, and professor of neurology at the National Hospital for Neurology and Neurosurgery, UCLH and the Royal Free London Hospital, London, UK. He is currently head of the department of clinical and movement neurosciences at UCL Queen Square Institute of Neurology. He is a member of the board of the Oxford University Hospitals Board. He was appointed to the NHS Reconfiguration Board in 2019.
Professor Schapira’s research interests include the molecular and clinical aspects of neurodegenerative diseases, with special emphasis on Parkinson disease and other movement disorders. He has over 450 peer-reviewed publications with more than 35 in Nature or Lancet series journals, and has edited over 15 books on various aspects of neurology including the textbook Neurology and Clinical Neuroscience. His H-index is 97 (Thomson, WoS), 121 (Google Scholar) and he has 16 Citation Classics (>400 citations). He is on the 2018 list of the world’s most highly cited researchers (Clarivate).
Professor Schapira is the recipient of the Harveian Medal, the Royal College of Physicians Clinical Science Prize, the European Prize for Clinical Science, the 1999 Opprecht Foundation Award and the Duchenne Prize. He was elected a fellow of the Academy of Medical Sciences in 1999. He was appointed a senior investigator at the National Institutes of Health Research in 2012. He was editor-in-chief of the European Journal 2006-2019.
Other movement disorders
Molecular and clinical prodrome of Parkinson disease: implications for treatment. Schapira AH, Tolosa E. Nat Rev Neurol. 2010 Jun;6(6):309-17. Epub 2010 May 18.
Missing pieces in the Parkinson's disease puzzle. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G. Nat Med. 2010 Jun;16(6):653-61. Epub 2010 May 23. Review.
Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Schapira AH, Agid Y, Barone P, Jenner P, Lemke MR, Poewe W, Rascol O, Reichmann H, Tolosa E. Eur J Neurol. 2009 Oct;16(10):1090-9. Epub 2009 Aug 30. Review.
Drug-induced fibrotic valvular heart disease. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Lancet. 2009 Aug 15;374(9689):577-85. Review.
Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Grünewald A, Gegg ME, Taanman JW, King RH, Kock N, Klein C, Schapira AH. Exp Neurol. 2009 Sep;219(1):266-73. Epub 2009 Jun 3.
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Chaudhuri KR, Schapira AH. Lancet Neurol. 2009 May;8(5):464-74. Review.